Protalix BioTherapeutics Bilan de santé
Santé financière contrôle des critères 6/6
Protalix BioTherapeutics has a total shareholder equity of $28.6M and total debt of $20.4M, which brings its debt-to-equity ratio to 71.4%. Its total assets and total liabilities are $91.5M and $63.0M respectively.
Informations clés
71.4%
Ratio d'endettement
US$20.42m
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$45.03m |
| Fonds propres | US$28.58m |
| Total du passif | US$62.96m |
| Total des actifs | US$91.54m |
Mises à jour récentes de la santé financière
Recent updates
Analyse de la situation financière
Passif à court terme: PBDA's short term assets ($77.4M) exceed its short term liabilities ($58.0M).
Passif à long terme: PBDA's short term assets ($77.4M) exceed its long term liabilities ($5.0M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: PBDA has more cash than its total debt.
Réduire la dette: PBDA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: PBDA has sufficient cash runway for more than 3 years based on its current free cash flow.
Prévisions de trésorerie: PBDA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 0.6% each year